Evidence map›Paper›PMID 32986753›Full record

ArticlePloS one2020

Whole-exome sequencing of 79 xenografts as a potential approach for the identification of genetic variants associated with sensitivity to cytotoxic anticancer drugs.

Chihiro Udagawa, Yasushi Sasaki, Yasuhiro Tanizawa, Hiroshi Suemizu, Yasuyuki Ohnishi, Yasukazu Nakamura, Takashi Tokino, Hitoshi Zembutsu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Chihiro UdagawaDepartment of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan.
Yasushi SasakiBiology, Department of Liberal Arts and Sciences Center for Medical Education, Sapporo Medical University, Sapporo, Japan.ORCID 0000-0002-3500-8059
Yasuhiro TanizawaDepartment of Informatics, National Institute of Genetics, Mishima, Japan.
Hiroshi SuemizuLaboratory Animal Research Department, Central Institute for Experimental Animals, Kawasaki, Japan.
Yasuyuki OhnishiLaboratory Animal Research Department, Central Institute for Experimental Animals, Kawasaki, Japan.
Yasukazu NakamuraDepartment of Informatics, National Institute of Genetics, Mishima, Japan.
Takashi TokinoDepartment of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University, Sapporo, Japan.
Hitoshi ZembutsuDepartment of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0002-1674-1968
Central Institute for Experimental Animals · JPNational Institute of Genetics · JPSapporo Medical University · JPNational Cancer Center Hospital East · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy response remains unpredictable in most patients with cancer. In this study, we performed whole-exome sequencing of 79 cancer xenografts derived from human cancer tissues to identify genetic predictors of chemosensitivity to nine cytotoxic anticancer drugs. Xenografts were harvested from 12 organs with cancer and implanted into nude mice. The mice were exposed to one of nine cytotoxic anticancer drugs (5-fluorouracil, nimustine, adriamycin, cyclophosphamide, cisplatin, mitomycin C, methotrexate, vincristine, and vinblastine) to assess the correlation between chemosensitivity response and variant allele frequency. We found 162 candidate variants that were possibly associated with chemosensitivity to one or more of the nine anticancer drugs (P < 0.01). In a subgroup analysis of breast and gastric cancer xenografts, 78 and 67 variants, respectively, were possibly associated with chemosensitivity. This approach may help to contribute to the development of personalized treatments that may allow for the prescription of optimal chemotherapy regimens among patients with cancer.

Indexed as

Genetic VariationAnimalsAntineoplastic AgentsCytotoxinsDrug Resistance, NeoplasmExome SequencingHeterograftsHumansMiceMice, Inbred BALB CMice, NudeNeoplasmsTreatment OutcomeXenograft Model Antitumor AssaysAntineoplastic AgentsCytotoxins

Identifiers

PMID32986753
PMCPMC7521756
OpenAlexW3091301100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.